

SETTING THE SCENE:



PHILIPPE AMOUYEL

French Foundation of Scientific Co-operation in
Alzheimer's Disease, France




EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



VISION EUROPE 2030

Bridging the Innovation Gap: Precision
Neurology for the Next Decade



September 2-3, 2025 | Club University Foundation



Prof. Philippe Amouyel

Public Health Department Lille University Hospital Fondation Alzheimer



FONDATION
ALZHEIMER




Université
de Lille



Hôpital Régional
Universitaire de Lille



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



Context

*Neuro-oncology Neurovascular diseases Epilepsy Neurocognitive diseases
Neurogenetic diseases TBI Parkinson Multiple sclerosis*

Neurological Diseases




Research -> Translation-> Clinic

*Clinical symptoms Genomics Proteomics Transcriptomics Electronic Medical
Neuropsychological symptoms Metagenomics Metabolomics Records*



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



SWOT ANALYSIS

Strengths



Weaknesses

Fragmentation of 27 countries

Lack of scientific strategic investments

UK outside of EU

Weak AI implementation among european physicians and scientists

Opportunities



**EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE**


Threats

Economical crisis


Tariffs

Unstability

Dependence on non european countries for hightech




Genomics of AD – European cohorts



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet 54, 412–436 (2022) and
Mega-meta: Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementia. Nat Genet (under revision)



JPND 2011–2025 publications

2,657 publications from WOS corecollection

1019 in Neurosciences

781 in Clinical Neurology

265 in Biochemistry and Molecular Biology

213 in Cell Biology

202 in Multidisciplinary Sciences

197 in Psychiatry

187 in Geriatrics Gerontology

91 in Genetics Heredity

87 in Medicine Research Experimentation

61 in Chemistry Multidisciplinary




EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



JPND 2011–2025 citations

Times Cited and Publications Over Time



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

JPND 2019–2023 innovation



8 patent applications

OligoFIT, PMI-AD,
NeuroPhage, Iron, Sleep,
NIPARK, DynaSti,
ORGTHERAPY and
DIPPA-FTD



9 patents pending examination

PDWALK, OligoFIT, PMI-AD, DEBBIE,
NeuroPhage,
Iron Sleep, DynaSti, PREADAPT and
ORGTHERAPY



5 licenses granted on IP rights



PDWALK, PMI-AD,
IronSleep, EU-FINGERS
and SORLA-FIX

2 licensed in or acquired a patent owned by another Organization

IronSleep and NEURIPIDES



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



LIGUE NATIONALE
ALZHEIMER LIGA
ASBL/VZW/VOG

Pre Diagnostics

Alzheimer
Society
CANADA

Bioventix

ONWARD

AC Immune

AstraZeneca

Key Issues to be tackled (*not only for PrecisionNeurology*)

- Reintegrate the UK into the European medical and scientific community.
- Continue reducing fragmentation among European countries.
- Invest in a European sovereign cloud for medical data.
Invest in European AI companies developing tools to analyze this data.
Increase the budget for the upcoming European Brain Health Partnership (starting January 1, 2026).



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE






One Actionable Policy


Rcommendation

**Invest in a European
sovereign cloud for
medical data**



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE





« It is far more important to know what person has the disease than what disease the person has » (attributed to Hippocrates)



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

